Abstract
Diseases at the molecular level are complex and patient dependent, necessitating development of strategies that enable precision treatment to optimize clinical outcomes. Organoid technology has recently been shown to have the potential to recapitulate the in vivo characteristics of the original individual's tissue in a three-dimensional in vitro culture system. Here, we present a quantitative mass-spectrometry-based proteomic analysis and a comparative transcriptomic analysis of human colorectal tumor and healthy organoids derived, in parallel, from seven patients. Although gene and protein signatures can be derived to distinguish the tumor organoid population from healthy organoids, our data clearly reveal that each patient possesses a distinct organoid signature at the proteomic level. We demonstrate that a personalized patient-specific organoid proteome profile can be related to the diagnosis of a patient and with future development contribute to the generation of personalized therapies.
Original language | English |
---|---|
Pages (from-to) | 263-274 |
Number of pages | 12 |
Journal | Cell Reports |
Volume | 18 |
Issue number | 1 |
DOIs | |
Publication status | Published - 3 Jan 2017 |
Keywords
- proteomics
- organoids
- mass spectrometry
- colorectal cancer